Sommerhoff Christian P, Avrutina Olga, Schmoldt Hans-Ulrich, Gabrijelcic-Geiger Dusica, Diederichsen Ulf, Kolmar Harald
Division of Clinical Chemistry and Clinical Biochemistry, Surgical Department, Ludwig-Maximilians-University Munich, Nussbaumstrasse 20, D-80336 Munich, Germany.
J Mol Biol. 2010 Jan 8;395(1):167-75. doi: 10.1016/j.jmb.2009.10.028. Epub 2009 Oct 21.
Here we report the design, chemical and recombinant synthesis, and functional properties of a series of novel inhibitors of human mast cell tryptase beta, a protease of considerable interest as a therapeutic target for the treatment of allergic asthma and inflammatory disorders. These inhibitors are derived from a linear variant of the cyclic cystine knot miniprotein MCoTI-II, originally isolated from the seeds of Momordica cochinchinensis. A synthetic cyclic miniprotein that bears additional positive charge in the loop connecting the N- and C-termini inhibits all monomers of the tryptase beta tetramer with an overall equilibrium dissociation constant K(i) of 1 nM and thus is one of the most potent proteinaceous inhibitors of tryptase beta described to date. These cystine knot miniproteins may therefore become valuable scaffolds for the design of a new generation of tryptase inhibitors.
在此,我们报告了一系列新型人肥大细胞β-胰蛋白酶抑制剂的设计、化学合成与重组合成及其功能特性。β-胰蛋白酶作为治疗过敏性哮喘和炎症性疾病的治疗靶点,备受关注。这些抑制剂源自环胱氨酸结微型蛋白MCoTI-II的线性变体,MCoTI-II最初是从罗汉果种子中分离得到的。一种在连接N端和C端的环中带有额外正电荷的合成环微型蛋白,以1 nM的总平衡解离常数K(i)抑制β-胰蛋白酶四聚体的所有单体,因此是迄今为止所描述的最有效的β-胰蛋白酶蛋白质抑制剂之一。因此,这些胱氨酸结微型蛋白可能成为设计新一代胰蛋白酶抑制剂的有价值的支架。